Selected research
Market Outlook & Growth Opportunities
Global PCR-based Mycoplasma Testing Service Market Outlook and Growth Opportunities 2026
Market perspective
The global PCR-based Mycoplasma Testing Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for PCR-based Mycoplasma Testing Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for PCR-based Mycoplasma Testing Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for PCR-based Mycoplasma Testing Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the PCR-based Mycoplasma Testing Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the PCR-based Mycoplasma Testing Service market include Charles River Laboratories International, Thermo Fisher Scientific, SGS, Bionique Testing Laboratories, WuXi AppTec, Labcorp, IDEXX BioAnalytics, WiCell and Creative Biogene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global PCR-based Mycoplasma Testing Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of PCR-based Mycoplasma Testing Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents PCR-based Mycoplasma Testing Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global PCR-based Mycoplasma Testing Service market.
PCR-based Mycoplasma Testing Service Segment by Company
Charles River Laboratories International
Thermo Fisher Scientific
SGS
Bionique Testing Laboratories
WuXi AppTec
Labcorp
IDEXX BioAnalytics
WiCell
Creative Biogene
Eurofins Scientific
Hylabs
JOINN Laboratories
Shimadzu Diagnostics
CellSafe
FullHope Biomedical
Syngene International
Beyotime
CTI Cert
Shenke Bio
PCR-based Mycoplasma Testing Service Segment by Type
Product Release Testing
Contamination Investigation Testing
Regulatory Compliance Testing
Others
PCR-based Mycoplasma Testing Service Segment by Application
Biopharmaceutical Companies
Contract Research/Manufacturing Organizations (CROs/CMOs)
Universities and Research Institutions
Others
PCR-based Mycoplasma Testing Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global PCR-based Mycoplasma Testing Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the PCR-based Mycoplasma Testing Service key companies, revenue, market share, and recent developments.
3. To split the PCR-based Mycoplasma Testing Service breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions PCR-based Mycoplasma Testing Service market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify PCR-based Mycoplasma Testing Service significant trends, drivers, influence factors in global and regions.
6. To analyze PCR-based Mycoplasma Testing Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCR-based Mycoplasma Testing Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PCR-based Mycoplasma Testing Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCR-based Mycoplasma Testing Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PCR-based Mycoplasma Testing Service industry.
Chapter 3: Detailed analysis of PCR-based Mycoplasma Testing Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of PCR-based Mycoplasma Testing Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of PCR-based Mycoplasma Testing Service in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Product Release Testing
- Contamination Investigation Testing
- Regulatory Compliance Testing
- Others
Applications
- Biopharmaceutical Companies
- Contract Research/Manufacturing Organizations (CROs/CMOs)
- Universities and Research Institutions
- Others
Companies covered
- Charles River Laboratories International
- Thermo Fisher Scientific
- SGS
- Bionique Testing Laboratories
- WuXi AppTec
- Labcorp
- IDEXX BioAnalytics
- WiCell
- Creative Biogene
- Eurofins Scientific
- Hylabs
- JOINN Laboratories
- Shimadzu Diagnostics
- CellSafe
- FullHope Biomedical
- Syngene International
- Beyotime
- CTI Cert
- Shenke Bio
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global PCR-based Mycoplasma Testing Service Market Size, 2021 VS 2025 VS 2032
- 1.3 Global PCR-based Mycoplasma Testing Service Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 PCR-based Mycoplasma Testing Service Market Dynamics
- 2.1 PCR-based Mycoplasma Testing Service Industry Trends
- 2.2 PCR-based Mycoplasma Testing Service Industry Drivers
- 2.3 PCR-based Mycoplasma Testing Service Industry Opportunities and Challenges
- 2.4 PCR-based Mycoplasma Testing Service Industry Restraints
3 PCR-based Mycoplasma Testing Service Market by Company
- 3.1 Global PCR-based Mycoplasma Testing Service Company Revenue Ranking in 2025
- 3.2 Global PCR-based Mycoplasma Testing Service Revenue by Company (2021-2026)
- 3.3 Global PCR-based Mycoplasma Testing Service Company Ranking (2024-2026)
- 3.4 Global PCR-based Mycoplasma Testing Service Company Manufacturing Base and Headquarters
- 3.5 Global PCR-based Mycoplasma Testing Service Company Product Type and Application
- 3.6 Global PCR-based Mycoplasma Testing Service Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global PCR-based Mycoplasma Testing Service Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 PCR-based Mycoplasma Testing Service Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 PCR-based Mycoplasma Testing Service Market by Type
- 4.1 PCR-based Mycoplasma Testing Service Type Introduction
- 4.1.1 Product Release Testing
- 4.1.2 Contamination Investigation Testing
- 4.1.3 Regulatory Compliance Testing
- 4.1.4 Others
- 4.2 Global PCR-based Mycoplasma Testing Service Sales Value by Type
- 4.2.1 Global PCR-based Mycoplasma Testing Service Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global PCR-based Mycoplasma Testing Service Sales Value by Type (2021-2032)
- 4.2.3 Global PCR-based Mycoplasma Testing Service Sales Value Share by Type (2021-2032)
5 PCR-based Mycoplasma Testing Service Market by Application
- 5.1 PCR-based Mycoplasma Testing Service Application Introduction
- 5.1.1 Biopharmaceutical Companies
- 5.1.2 Contract Research/Manufacturing Organizations (CROs/CMOs)
- 5.1.3 Universities and Research Institutions
- 5.1.4 Others
- 5.2 Global PCR-based Mycoplasma Testing Service Sales Value by Application
- 5.2.1 Global PCR-based Mycoplasma Testing Service Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global PCR-based Mycoplasma Testing Service Sales Value by Application (2021-2032)
- 5.2.3 Global PCR-based Mycoplasma Testing Service Sales Value Share by Application (2021-2032)
6 PCR-based Mycoplasma Testing Service Regional Value Analysis
- 6.1 Global PCR-based Mycoplasma Testing Service Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global PCR-based Mycoplasma Testing Service Sales Value by Region (2021-2032)
- 6.2.1 Global PCR-based Mycoplasma Testing Service Sales Value by Region: 2021-2026
- 6.2.2 Global PCR-based Mycoplasma Testing Service Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America PCR-based Mycoplasma Testing Service Sales Value (2021-2032)
- 6.3.2 North America PCR-based Mycoplasma Testing Service Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe PCR-based Mycoplasma Testing Service Sales Value (2021-2032)
- 6.4.2 Europe PCR-based Mycoplasma Testing Service Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific PCR-based Mycoplasma Testing Service Sales Value (2021-2032)
- 6.5.2 Asia-Pacific PCR-based Mycoplasma Testing Service Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America PCR-based Mycoplasma Testing Service Sales Value (2021-2032)
- 6.6.2 South America PCR-based Mycoplasma Testing Service Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa PCR-based Mycoplasma Testing Service Sales Value (2021-2032)
- 6.7.2 Middle East & Africa PCR-based Mycoplasma Testing Service Sales Value Share by Country, 2025 VS 2032
7 PCR-based Mycoplasma Testing Service Country-level Value Analysis
- 7.1 Global PCR-based Mycoplasma Testing Service Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global PCR-based Mycoplasma Testing Service Sales Value by Country (2021-2032)
- 7.2.1 Global PCR-based Mycoplasma Testing Service Sales Value by Country (2021-2026)
- 7.2.2 Global PCR-based Mycoplasma Testing Service Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.3.2 USA PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.7.2 France PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.14.2 China PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.17.2 India PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt PCR-based Mycoplasma Testing Service Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt PCR-based Mycoplasma Testing Service Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt PCR-based Mycoplasma Testing Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Charles River Laboratories International
- 8.1.1 Charles River Laboratories International Company Information
- 8.1.2 Charles River Laboratories International Business Overview
- 8.1.3 Charles River Laboratories International PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.1.4 Charles River Laboratories International PCR-based Mycoplasma Testing Service Product Portfolio
- 8.1.5 Charles River Laboratories International Recent Developments
- 8.2 Thermo Fisher Scientific
- 8.2.1 Thermo Fisher Scientific Company Information
- 8.2.2 Thermo Fisher Scientific Business Overview
- 8.2.3 Thermo Fisher Scientific PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.2.4 Thermo Fisher Scientific PCR-based Mycoplasma Testing Service Product Portfolio
- 8.2.5 Thermo Fisher Scientific Recent Developments
- 8.3 SGS
- 8.3.1 SGS Company Information
- 8.3.2 SGS Business Overview
- 8.3.3 SGS PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.3.4 SGS PCR-based Mycoplasma Testing Service Product Portfolio
- 8.3.5 SGS Recent Developments
- 8.4 Bionique Testing Laboratories
- 8.4.1 Bionique Testing Laboratories Company Information
- 8.4.2 Bionique Testing Laboratories Business Overview
- 8.4.3 Bionique Testing Laboratories PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.4.4 Bionique Testing Laboratories PCR-based Mycoplasma Testing Service Product Portfolio
- 8.4.5 Bionique Testing Laboratories Recent Developments
- 8.5 WuXi AppTec
- 8.5.1 WuXi AppTec Company Information
- 8.5.2 WuXi AppTec Business Overview
- 8.5.3 WuXi AppTec PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.5.4 WuXi AppTec PCR-based Mycoplasma Testing Service Product Portfolio
- 8.5.5 WuXi AppTec Recent Developments
- 8.6 Labcorp
- 8.6.1 Labcorp Company Information
- 8.6.2 Labcorp Business Overview
- 8.6.3 Labcorp PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.6.4 Labcorp PCR-based Mycoplasma Testing Service Product Portfolio
- 8.6.5 Labcorp Recent Developments
- 8.7 IDEXX BioAnalytics
- 8.7.1 IDEXX BioAnalytics Company Information
- 8.7.2 IDEXX BioAnalytics Business Overview
- 8.7.3 IDEXX BioAnalytics PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.7.4 IDEXX BioAnalytics PCR-based Mycoplasma Testing Service Product Portfolio
- 8.7.5 IDEXX BioAnalytics Recent Developments
- 8.8 WiCell
- 8.8.1 WiCell Company Information
- 8.8.2 WiCell Business Overview
- 8.8.3 WiCell PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.8.4 WiCell PCR-based Mycoplasma Testing Service Product Portfolio
- 8.8.5 WiCell Recent Developments
- 8.9 Creative Biogene
- 8.9.1 Creative Biogene Company Information
- 8.9.2 Creative Biogene Business Overview
- 8.9.3 Creative Biogene PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.9.4 Creative Biogene PCR-based Mycoplasma Testing Service Product Portfolio
- 8.9.5 Creative Biogene Recent Developments
- 8.10 Eurofins Scientific
- 8.10.1 Eurofins Scientific Company Information
- 8.10.2 Eurofins Scientific Business Overview
- 8.10.3 Eurofins Scientific PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.10.4 Eurofins Scientific PCR-based Mycoplasma Testing Service Product Portfolio
- 8.10.5 Eurofins Scientific Recent Developments
- 8.11 Hylabs
- 8.11.1 Hylabs Company Information
- 8.11.2 Hylabs Business Overview
- 8.11.3 Hylabs PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.11.4 Hylabs PCR-based Mycoplasma Testing Service Product Portfolio
- 8.11.5 Hylabs Recent Developments
- 8.12 JOINN Laboratories
- 8.12.1 JOINN Laboratories Company Information
- 8.12.2 JOINN Laboratories Business Overview
- 8.12.3 JOINN Laboratories PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.12.4 JOINN Laboratories PCR-based Mycoplasma Testing Service Product Portfolio
- 8.12.5 JOINN Laboratories Recent Developments
- 8.13 Shimadzu Diagnostics
- 8.13.1 Shimadzu Diagnostics Company Information
- 8.13.2 Shimadzu Diagnostics Business Overview
- 8.13.3 Shimadzu Diagnostics PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.13.4 Shimadzu Diagnostics PCR-based Mycoplasma Testing Service Product Portfolio
- 8.13.5 Shimadzu Diagnostics Recent Developments
- 8.14 CellSafe
- 8.14.1 CellSafe Company Information
- 8.14.2 CellSafe Business Overview
- 8.14.3 CellSafe PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.14.4 CellSafe PCR-based Mycoplasma Testing Service Product Portfolio
- 8.14.5 CellSafe Recent Developments
- 8.15 FullHope Biomedical
- 8.15.1 FullHope Biomedical Company Information
- 8.15.2 FullHope Biomedical Business Overview
- 8.15.3 FullHope Biomedical PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.15.4 FullHope Biomedical PCR-based Mycoplasma Testing Service Product Portfolio
- 8.15.5 FullHope Biomedical Recent Developments
- 8.16 Syngene International
- 8.16.1 Syngene International Company Information
- 8.16.2 Syngene International Business Overview
- 8.16.3 Syngene International PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.16.4 Syngene International PCR-based Mycoplasma Testing Service Product Portfolio
- 8.16.5 Syngene International Recent Developments
- 8.17 Beyotime
- 8.17.1 Beyotime Company Information
- 8.17.2 Beyotime Business Overview
- 8.17.3 Beyotime PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.17.4 Beyotime PCR-based Mycoplasma Testing Service Product Portfolio
- 8.17.5 Beyotime Recent Developments
- 8.18 CTI Cert
- 8.18.1 CTI Cert Company Information
- 8.18.2 CTI Cert Business Overview
- 8.18.3 CTI Cert PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.18.4 CTI Cert PCR-based Mycoplasma Testing Service Product Portfolio
- 8.18.5 CTI Cert Recent Developments
- 8.19 Shenke Bio
- 8.19.1 Shenke Bio Company Information
- 8.19.2 Shenke Bio Business Overview
- 8.19.3 Shenke Bio PCR-based Mycoplasma Testing Service Revenue and Gross Margin (2021-2026)
- 8.19.4 Shenke Bio PCR-based Mycoplasma Testing Service Product Portfolio
- 8.19.5 Shenke Bio Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst